• Novacyt posted a loss after tax attributable to owners of GBP 5.79 million for the six months ended June 30, 2026.
• Revenue rose 18% to GBP 11.56 million versus the six months ended June 30, 2025.
• Operating loss after other operating income/expense narrowed 29% to GBP 5.11 million.
• Net cash used in operating activities improved 17% to GBP 4.55 million, while cash and cash equivalents fell to GBP 8.92 million.
• The group acquired Southern Cross Diagnostics on March 2, 2026; it contributed GBP 1.84 million revenue and GBP 191,000 profit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novacyt SA published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.